"uuid:ID","instanceType","versionIdentifier","id","rationale"
"dbee1079-df46-4bc1-a68a-091ecdf602f2","StudyVersion","2","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
